NLRP3 inflammasome in neurodegenerative disease
Translational Research · 2023-02 · 252 · 21-33
DOI: 10.1016/j.trsl.2022.08.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Research, 2023-02. Verfasst von Faith L Anderson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire. Hauptthemen laut MEDLINE: Inflammasomes, Neurodegenerative Diseases. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 259 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, National Institute of Environmental Health Sciences, Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire.
- Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire. Electronic address: matthew.c.havrda@dartmouth.edu.
Förderung
- NIEHS NIH HHS
- National Institute of Environmental Health Sciences
- Michael J. Fox Foundation for Parkinson's Research
- Ministry for Culture and Heritage, New Zealand
- National Institutes of Health
Zitieren
APA
Anderson, F. L., Biggs, K. E., Rankin, B. E., & Havrda, M. C. (2023). NLRP3 inflammasome in neurodegenerative disease. Translational Research, 252, 21-33. https://doi.org/10.1016/j.trsl.2022.08.006
Vancouver
Anderson FL, Biggs KE, Rankin BE, Havrda MC. NLRP3 inflammasome in neurodegenerative disease. Translational Research. 2023;252:21-33. doi:10.1016/j.trsl.2022.08.006
BibTeX
@article{Anderson2023,
author = {Anderson, Faith L and Biggs, Karl E and Rankin, Brynn E and Havrda, Matthew C},
title = {NLRP3 inflammasome in neurodegenerative disease},
journal = {Translational Research},
year = {2023},
volume = {252},
pages = {21--33},
doi = {10.1016/j.trsl.2022.08.006}
}
EUVIMED